{"entity":{"id":"immortal-time-bias","kind":"term","name":"Immortal time bias","aka":["guarantee-time bias","time-dependent treatment assignment bias"],"tldr":"A group can appear to survive longer simply because people had to survive long enough to enter it. The starting time and rules for group membership are part of a fair comparison.","summary":"Immortal time is a period during which an outcome cannot occur for someone to qualify for a later-defined exposure group. Misclassifying or excluding that period can bias an observational treatment comparison. Primary methodological work demonstrated the effect using different cohort designs and a lung cancer example. Aligning eligibility, treatment assignment and follow-up is essential; calling an analysis adjusted does not establish that this timing problem was addressed.","asOf":"2026-11-08","links":[{"label":"Primary immortal-time bias analysis (2008)","url":"https://doi.org/10.1093/aje/kwm324"},{"label":"Target-trial emulation framework (2016)","url":"https://doi.org/10.1093/aje/kwv254"}],"tags":[],"related":["real-world-evidence","target-trial-emulation","landmark-survival"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Trials"},"route":"/terms/immortal-time-bias/","neighbours":{"term":[{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","route":"/terms/measurement-to-benefit-evidence/"},{"id":"landmark-survival","kind":"term","name":"Landmark and milestone survival (5-year survival, median follow-up)","route":"/terms/landmark-survival/"},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"},{"id":"target-trial-emulation","kind":"term","name":"Target-trial emulation","route":"/terms/target-trial-emulation/"}]}}